Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoniazid + rifampicin
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Isoniazid + rifampicin is a fixed-dose combination of two antibiotics used primarily to treat tuberculosis (TB). Isoniazid inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall, by targeting enoyl-acyl carrier protein reductase after activation by bacterial catalase-peroxidase. Rifampicin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing RNA synthesis and subsequent protein production. This combination is typically administered orally and may be used with other antituberculosis medications. It appears on the World Health Organization's List of Essential Medicines due to its importance in TB treatment[1][2][5][6].
- Brand names
- IsonaRifRifamateR-CinexMacox PlusAkt 2Akt2Akt-2MycocoxAkuritVicox 2Vicox2Vicox-2Akurit KidRF CompoundExact 2Exact2Exact-2Scc 2 LWScc2 LWScc-2 LW
- Other names
- isoniazid/rifampicinisoniazid/rifampin
02
Targets
InhArpoB (DNA-directed RNA polymerase subunit beta)
Beyond the preview
Go deeper on isoniazid + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoniazid + rifampicin.